<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">russjcardiol</journal-id><journal-title-group><journal-title xml:lang="ru">Российский кардиологический журнал</journal-title><trans-title-group xml:lang="en"><trans-title>Russian Journal of Cardiology</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1560-4071</issn><issn pub-type="epub">2618-7620</issn><publisher><publisher-name>«SILICEA-POLIGRAF» LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.15829/1560-4071-2019-1-7-11</article-id><article-id custom-type="elpub" pub-id-type="custom">russjcardiol-3111</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ СТАТЬИ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ORIGINAL ARTICLES</subject></subj-group></article-categories><title-group><article-title>Состояние магистральных артерий, сосудистый возраст у больных артериальной гипертензией и ожирением: роль лептина и адипонектина</article-title><trans-title-group xml:lang="en"><trans-title>The state of the main arteries, vascular age in patients with arterial hypertension and obesity: the role of leptin and adiponectin</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-3306-0312</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Стаценко</surname><given-names>М. Е.</given-names></name><name name-style="western" xml:lang="en"><surname>Statsenko</surname><given-names>M. E.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Михаил Евгеньевич Стаценко  — доктор медицинских наук, профессор, проректор по научной работе, заведующий кафедрой внутренних болезней педиатрического и стоматологического факультетов</p><p>SPIN-код: 3646-5743</p></bio><email xlink:type="simple">mestatsenko@rambler.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-6232-4583</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Деревянченко</surname><given-names>М. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Derevyanchenko</surname><given-names>M. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Мария Владимировна Деревянченко — кандидат медицинских наук, доцент кафедры внутренних болезней педиатрического и стоматологического факультетов</p><p>SPIN-код: 6754-4297</p></bio><email xlink:type="simple">derevjanchenko@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБОУ ВО "Волгоградский государственный медицинский университет" Минздрава России</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Volgograd State Medical University</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2019</year></pub-date><pub-date pub-type="epub"><day>07</day><month>02</month><year>2019</year></pub-date><volume>0</volume><issue>1</issue><fpage>7</fpage><lpage>11</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Стаценко М.Е., Деревянченко М.В., 2019</copyright-statement><copyright-year>2019</copyright-year><copyright-holder xml:lang="ru">Стаценко М.Е., Деревянченко М.В.</copyright-holder><copyright-holder xml:lang="en">Statsenko M.E., Derevyanchenko M.V.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://russjcardiol.elpub.ru/jour/article/view/3111">https://russjcardiol.elpub.ru/jour/article/view/3111</self-uri><abstract><sec><title>Цель</title><p>Цель. Изучить состояние магистральных артерий, сосудистый возраст во взаимосвязи с уровнем лептина и адипонектина у больных артериальной гипертензией (АГ) и ожирением.</p></sec><sec><title>Материал и методы</title><p>Материал и методы. 120 пациентов с АГ II стадии 45-65 лет были разделены на 3 группы в зависимости от индекса массы тела (ИМТ). 1 группа представлена пациентами с АГ и нормальным ИМТ, 2 — пациентами с АГ и избыточным ИМТ, 3 — пациентами с АГ в сочетании с ожирением. Проводили стандартное клиническое обследование, оценивали жесткость сосудистой стенки путем измерения скорости распространения пульсовой волны (СРПВ) по сосудам мышечного и эластического (СРПВэ) типов, рассчитывали сосудистый возраст, определяли лабораторные маркеры ожирения.</p></sec><sec><title>Результаты</title><p>Результаты. Отмечен высокий процент выявления висцерального ожирения: 20,0% среди лиц с нормальным ИМТ, 64,4% среди лиц с избыточной массой тела и 100% среди лиц с ожирением (различия между 1 и 2, 1 и 3, 2 и 3 группами достоверны). Обнаружено статистически значимое увеличение СРПВэ у больных с АГ и ожирением в сравнении с больными с АГ и нормальной массой тела (9,8 [8,5; 11,3] vs 8,0 [7,9; 8,1] м/с). Сосудистый возраст был выше у пациентов с АГ и избыточной массой тела или ожирением в сравнении с пациентами с АГ и нормальной массой тела (670 [60,0; 76,0], 68,0 [60,0; 72,0] vs 58,0 [570; 60,0] лет, соответственно). Выявлены статистически значимый рост концентрации лептина (6,9 [4,5; 15,1] vs 19,0 [74; 42,7] vs 53,8 [38,4; 75,8] нг/мл), а также снижение концентрации адипонектина от 1 к 3 группе (44,9 [36,6; 55,8] vs 16,5 [12,5; 24,7] vs 18,6 [15,3; 22,4] нг/мл, соответственно). Корреляционный анализ обнаружил наличие высокодостоверных взаимосвязей между параметрами, характеризующими жесткость магистральных артерий и лабораторными маркерами ожирения.</p></sec><sec><title>Заключение</title><p>Заключение. Полученные данные свидетельствуют о негативном влиянии гиперлептинемии и гипоадипонектинемии на эластичность сосудистой стенки магистральных артерий и величину сосудистого возраста у больных АГ при сочетании ее с избыточной массой тела или ожирением.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Aim</title><p>Aim. To study the state of the main arteries and vascular age in conjunction with the level of leptin and adiponectin in patients with arterial hypertension (AH) and obesity.</p></sec><sec><title>Material and methods</title><p>Material and methods. One hundred and twenty patients with AH stage II aged from 45 to 65 years were divided into 3 groups depending on body mass index (BMI). Group 1 was represented by patients with AH and normal BMI, the 2 group was represented by patients with AH and excessive BMI, the 3 group was represented by patients with AH in combination with obesity. A standard clinical examination was performed, the stiffness of the vascular wall was measured by measuring the pulse wave velocity (PWV) of the muscle and elastic vessels (PWVe), vascular age was calculated, and the laboratory markers of obesity were determined.</p></sec><sec><title>Results</title><p>Results. High percentage of visceral obesity was observed: 20,0% among people with normal BMI, 64,4% among overweight people and 100% among people with obesity (differences between 1 and 2, 1 and 3, 2 and 3 groups are reliable). A statistically significant increase in PWVe was detected in patients with AH and obesity in comparison with patients with AH and normal body weight (9,8 [8,5; 11,3] vs 8,0 [79; 8,1] m/s). Vascular age was higher in patients with AH and overweight or obesity compared with patients with AH and normal weight (670 [60,0; 76,0], 68,0 [60,0; 72,0] vs 58,0 [57,0; 60,0] years, respectively). A statistically significant increase in the concentration of leptin (6,9 [4,5; 15,1] vs 19,0 [74; 42,7] vs 53,8 [38,4; 75,8] ng/ml) was detected, as well as a decrease in adiponectin concentration from the 1 to the 3 group (44,9 [36,6; 55,8] vs 16,5 [12,5; 24,7] vs 18,6 [15,3; 22,4] ng/ml, respectively).</p><p>Correlation analysis revealed the presence of highly reliable relationships between the parameters of rigidity of the main arteries and laboratory markers of obesity.</p></sec><sec><title>Conclusion</title><p>Conclusion. The results indicated a negative effect of hyperleptinemia and hypoadiponectinemia on the elasticity of the vascular wall of the main arteries and the vascular age in hypertensive patients with its combination with overweight or obesity.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>артериальная гипертензия</kwd><kwd>абдоминальное ожирение</kwd><kwd>висцеральное ожирение</kwd><kwd>ригидность магистральных артерий</kwd><kwd>сосудистый возраст</kwd><kwd>адипокины</kwd><kwd>лептин</kwd><kwd>адипонектин</kwd></kwd-group><kwd-group xml:lang="en"><kwd>arterial hypertension</kwd><kwd>abdominal obesity</kwd><kwd>visceral obesity</kwd><kwd>rigidity of the main arteries</kwd><kwd>vascular age</kwd><kwd>adipokines</kwd><kwd>leptin</kwd><kwd>adiponectin</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH Guidelines for the Management of Arterial Hypertension. Eur Heart J. 2018;39(33):3021-104. doi:10.1093/eurheartj/ehy339.</mixed-citation><mixed-citation xml:lang="en">Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH Guidelines for the Management of Arterial Hypertension. Eur Heart J. 2018;39(33):3021-104. doi:10.1093/eurheartj/ehy339.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Стаценко М. Е., Деревянченко М. В. Роль системного воспаления в снижении эластичности магистральных артерий и прогрессировании эндотелиальной дисфункции у больных артериальной гипертензией в сочетании с ожирением, сахарным диабетом 2 типа. Российский кардиологический журнал. 2018;23(4):32-6. doi:10.15829/1560-4071-2018-4-32-36.</mixed-citation><mixed-citation xml:lang="en">Statsenko ME, Derevyanchenko MV. The role of systemic inflammation in reducing the elasticity of the main arteries and the progression of endothelial dysfunction in patients with arterial hypertension in combination with obesity, type 2 diabetes. Russ J Cardiol. 2018;23(4):32-6. (In Russ.) doi:10.15829/1560-4071-2018-4-32-36.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">D’Agostino RB, Vasan RS, Pencina MJ. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation. 2008;117(6):743-53. doi:10.1161/CIRCULATIONAHA.107.699579.</mixed-citation><mixed-citation xml:lang="en">D’Agostino RB, Vasan RS, Pencina MJ. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation. 2008;117(6):743-53. doi:10.1161/CIRCULATIONAHA.107.699579.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Троицкая Е. А., Вельмакин С. В., Кобалава Ж. Д. Концепция сосудистого возраста: новый инструмент оценки сердечно-сосудистого риска. Артериальная гипертензия. 2017;23(2):160-71. doi:10.18705/1607-419X-2017-23-2-160-171.</mixed-citation><mixed-citation xml:lang="en">Troitskaya YeA, Vel’makin SV, Kobalava ZhD. Vascular age concept: a new tool for cardiovascular risk assessment. Arterial’naya gipertenziya. 2017;23(2):160-71. (In Russ.) doi:10.18705/1607-419X-2017-23-2-160-171.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Dahlof B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT-BPLA): a multicenter randomised controlled trial. Lancet. 2005;366(948):895906. doi:10.1016/S0140-6736(05)67185-1.</mixed-citation><mixed-citation xml:lang="en">Dahlof B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT-BPLA): a multicenter randomised controlled trial. Lancet. 2005;366(948):895906. doi:10.1016/S0140-6736(05)67185-1.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Prieto-Merino D, Dobson J, Gupta AK et al. ASCORE: an up-to-date cardiovascular risk score for hypertensive patients reflecting contemporary clinical practice developed using the (ASCOT-BPLA) trial data. J Hum Hypertens. 2013;27(8):492-6. doi:10.1038/jhh.2013.3.</mixed-citation><mixed-citation xml:lang="en">Prieto-Merino D, Dobson J, Gupta AK et al. ASCORE: an up-to-date cardiovascular risk score for hypertensive patients reflecting contemporary clinical practice developed using the (ASCOT-BPLA) trial data. J Hum Hypertens. 2013;27(8):492-6. doi:10.1038/jhh.2013.3.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Zachariah JP, Hwang S, Hamburg NM, et al. Circulating adipokines and vascular function: cross-sectional associations in a community-based cohort. Hypertension. 2016 67(2):294300. doi:10.1161/HYPERTENSIONAHA.115.05949.</mixed-citation><mixed-citation xml:lang="en">Zachariah JP, Hwang S, Hamburg NM, et al. Circulating adipokines and vascular function: cross-sectional associations in a community-based cohort. Hypertension. 2016 67(2):294300. doi:10.1161/HYPERTENSIONAHA.115.05949.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Недогода С. В., Барыкина И. Н., Саласюк А. С. Национальные клинические рекомендации по ожирению: концепция и перспективы. Вестник Волгоградского государственного медицинского университета. 2017;1(61):134-40.</mixed-citation><mixed-citation xml:lang="en">Nedogoda SV, Barykina IN, Salasyuk AS. National clinical recommendations for obesity: concept and perspectives. Vestnik Volgogradskogo gosudarstvennogo meditsinskogo universiteta. 2017; 1(61): 134-40. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Шляхто Е. В., Недогода С. В., Конради А. О. Национальные клинические рекомендации. Диагностика, лечение, профилактика ожирения и ассоциированных с ним заболеваний. 2017. http://www.scardio.ru/content/Guidelines/project/Ozhirenie_klin_rek_proekt.pdf.</mixed-citation><mixed-citation xml:lang="en">Shlyakhto EV, Nedogoda SV, Konradi AO. National clinical recommendations. Diagnosis, treatment, prevention of obesity and associated diseases. 2017. (In Russ.) http://www.scardio.ru/content/Guidelines/project/Ozhirenie_klin_rek_proekt.pdf.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Стаценко МЕ, Деревянченко МВ. Функциональное состояние почек и сердечно-сосудистый риск у больных с артериальной гипертензией и ожирением: роль лептина и адипонектина. Нефрология 2018;22(5):51 -7. doi:10.24884/1561-6274-2018-22-5-51-57.</mixed-citation><mixed-citation xml:lang="en">Statsenko ME, Derevyanchenko MV. Renal function and cardiovascular risk in patients with arterial hypertension and obesity: the role of leptin and adiponectin. Nefrologiya. 2018;22(5):51-7. (In Russ.) doi:10.24884/1561-6274-2018-22-5-51-57.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Laurent S, Marais L, Boutouyrie P. The Noninvasive assessment of vascular aging. Can J Cardiol. 2016;32(5):669-79. doi:10.1016/j.cjca.2016.01.039.</mixed-citation><mixed-citation xml:lang="en">Laurent S, Marais L, Boutouyrie P. The Noninvasive assessment of vascular aging. Can J Cardiol. 2016;32(5):669-79. doi:10.1016/j.cjca.2016.01.039.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Tsai JP, Hsu BG, Lee CJ, et al. Serum leptin is a predictor for central arterial stiffness in hypertensive patients. Nephrology (Carlton). 2017;22(10):783-9. doi:10.1111/nep.12859.</mixed-citation><mixed-citation xml:lang="en">Tsai JP, Hsu BG, Lee CJ, et al. Serum leptin is a predictor for central arterial stiffness in hypertensive patients. Nephrology (Carlton). 2017;22(10):783-9. doi:10.1111/nep.12859.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Hall JE, do Carmo JM, da Silva AA, et al. Obesity-induced hypertension: interaction of neurohumoral and renal mechanisms. Circ Res. 2015;116(6):991-1006. doi: 10.1161/CIRCRESAHA.116.305697.</mixed-citation><mixed-citation xml:lang="en">Hall JE, do Carmo JM, da Silva AA, et al. Obesity-induced hypertension: interaction of neurohumoral and renal mechanisms. Circ Res. 2015;116(6):991-1006. doi: 10.1161/CIRCRESAHA.116.305697.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Nasrallah MP, Ziyadeh FN. Overview of the physiology and pathophysiology of leptin with special emphasis on its role in the kidney. Semin Nephrol. 2013;33(1):54-65. doi:10.1016/j.semnephrol.2012.12.005.</mixed-citation><mixed-citation xml:lang="en">Nasrallah MP, Ziyadeh FN. Overview of the physiology and pathophysiology of leptin with special emphasis on its role in the kidney. Semin Nephrol. 2013;33(1):54-65. doi:10.1016/j.semnephrol.2012.12.005.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Zha D, Wu X, Gao P. Adiponectin and its receptors in diabetic kidney disease: molecular mechanisms and clinical potential. Endocrinology. 2017; 158(7):2022-34. doi: 101210/en.2016-1765.</mixed-citation><mixed-citation xml:lang="en">Zha D, Wu X, Gao P. Adiponectin and its receptors in diabetic kidney disease: molecular mechanisms and clinical potential. Endocrinology. 2017; 158(7):2022-34. doi: 101210/en.2016-1765.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
